In this post, we will be taking a closer look at some of the most popular dermatology-related articles recently published across leading medical journals.

Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data

  • Journal of the American Academy of Dermatology
  • May 2024
  • The risk for venous thromboembolism (VTE) may be higher among patients with certain immune-mediated inflammatory diseases, but data on atopic dermatitis (AD) are limited. When compared to patients with rheumatoid arthritis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and psoriatic arthritis, patients with AD had lower risk of VTE.

Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia

  • JAMA Dermatology
  • April 2024
  • There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment. However, the efficacy of oral minoxidil for male AGA is yet to be evaluated in comparative therapeutic trials.

Ultrasound Surveillance in Melanoma Management: Bridging Diagnostic Promise with Real-World Adherence: A Systematic Review and Meta-Analysis

  • American Journal of Clinical Dermatology
  • April 2024
  • Ultrasound surveillance has become the new standard of care in stage III melanoma after the 2017 Multicenter Selective Lymphadenectomy Trial II (MSLT-II) demonstrated non-inferior 3-year survival compared with complete lymph node dissection.

Genetic Tools for Cell Lineage Tracing and Profiling Developmental Trajectories in the Skin

  • Journal of Investigative Dermatology
  • May 2024
  • In this review, we highlight cutting-edge methods for cell lineage tracing, including in organoids and model organisms, and explore how cutaneous biology researchers might leverage these techniques to elucidate the developmental programs that support the regenerative capacity and plasticity of the skin.

JAK inhibitors for the treatment of vitiligo

  • The Journal of Dermatological Science
  • March 2024
  • Recently, novel topical agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, have emerged. Ruxolitinib is the first approved in vitiligo therapy. Furthermore, ritlecitinib is currently under clinical trials for oral treatment of active vitiligo. In this review, we discuss the possibility of topical JAK inhibitors as promising options for the treatment of vitiligo with regard to their mechanism of action, efficacy and safety.

Rosacea: Pathogenesis and Therapeutic Correlates

  • Journal of Cutaneous Medicine and Surgery
  • March/April 2024
  • Rosacea is a chronic inflammatory condition of which there is no cure. The pathogenesis of rosacea is likely multifactorial, involving genetic and environmental contributions. Current understanding suggests that pro-inflammatory pathways involving cathelicidins and inflammasome complexes are central to rosacea pathogenesis. Common rosacea triggers modulate these pathways in a complex manner, which may contribute to the varying severity and clinical presentations of rosacea. Established and emerging rosacea treatments may owe their efficacy to their ability to target different players in these pro-inflammatory pathways. Improving our molecular understanding of rosacea will guide the development of new therapies and the use of combination therapies.

Allergic or Not: Final Interpretation of Doubtful Patch Test Reactions From the North American Contact Dermatitis Group, 2019–2020

  • Dermatitis®
  • March/April 2024
  • Doubtful patch test reactions generally do not meet criterion for positivity in patch testing. However, the North American Contact Dermatitis Group (NACDG) allows for doubtful reactions to be coded with a final determination of “allergic/positive” based on the temporal pattern, appearance, known characteristics of the allergen, and/or other supportive patch test reactions.

Depression As a Potential Contributing Factor in Hidradenitis Suppurativa and Associated Racial Gaps

  • Cutis
  • March 2024
  • The high prevalence of depression in individuals with HS and its association with systemic inflammation increases the likelihood that depression also may be a contributing etiology to HS. Because depression frequently has been discovered as a concomitant diagnosis in patients with HS, we hypothesize that there is a common susceptibility to depression in patients with HS, which we investigated through a literature search of articles published from 2000 to 2022 involving depression and HS.

Real-World Evidence Confirms Risk Stratification of the 31-GEP and i31-GEP in Prospectively Tested Patients with Stage I-III Cutaneous Melanoma

  • SKIN: Journal of Cutaneous Medicine
  • March 2024
  • Current American Joint Committee on Cancer (AJCC 8th edition) guidelines in patients with cutaneous melanoma (CM) separate them into risk categories based on the pathological tumor data of Breslow thickness, ulceration status, and sentinel lymph node status. The 31-gene expression profile was developed and prospectively validated to identify patients considered high or low risk by AJCC with low or high-risk tumor biology who may be over- or under-treated by current guidelines. To further advance personalized patient care, the 31-GEP result was integrated with clinical and pathological factors (i31-GEP for risk of recurrence, ROR) to provide a personalized, precise risk of tumor recurrence.

There you have it – a look at some of the most popular dermatology publications released in April 2024. Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2024 Guideline Central, All rights reserved.